Business Context and Reporting Period
Company: Agios Pharmaceuticals, Inc. (AGIO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Agios is a commercial-stage biopharmaceutical company focused on rare diseases, specifically hemolytic anemias. Its lead product, mitapivat, is marketed as PYRUKYND for Pyruvate Kinase (PK) deficiency and AQVESME for alpha- and beta-thalassemia. The company also maintains a pipeline including tebapivat (LR MDS/SCD), AG-181 (PKU), and AG-236 (Polycythemia Vera).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $54.0 million | $36.5 million | $26.8 million |
| Net (Loss) Income | $(412.8) million | $673.7 million | $(352.1) million |
| Operating Expenses | $526.2 million | $462.2 million | $418.3 million |
| Research & Development (R&D) | $339.5 million | $301.3 million | $295.5 million |
| Selling, General & Admin (SG&A) | $180.3 million | $156.8 million | $119.9 million |
| Cash, Cash Equivalents & Marketable Securities | $1.2 billion | $1.5 billion | N/A |
| Accumulated Deficit | $(561.7) million | $(148.9) million | $(822.6) million |
Note: 2024 Net Income was driven by non-recurring gains from the sale of Vorasidenib royalty rights ($889.1 million) and a milestone payment ($200.0 million).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 48% year-over-year to $54.0 million, driven by a 35% increase in U.S. product revenue ($49.2 million) and a significant increase in "Rest of World" revenue ($4.9 million) due to the Avanzanite distribution agreement.
- Return to Loss: The company returned to a net loss of $412.8 million in 2025, compared to a net income of $673.7 million in 2024. This shift is primarily due to the absence of the one-time $1.09 billion in gains recognized in 2024 from the Vorasidenib asset sales.
- Expense Increases: Operating expenses rose $63.9 million to $526.2 million. R&D expenses increased $38.2 million, largely due to higher clinical trial costs for tebapivat and a $10.0 million milestone payment to Alnylam. SG&A increased $23.5 million to support the commercial launch of AQVESME.
- Cash Position: Cash and marketable securities decreased by approximately $300 million to $1.2 billion, reflecting operating cash burn of $373.0 million, partially offset by investing activities.
Guidance, Outlook, and Risks
Outlook and Milestones
- AQVESME Launch: Commercially launched in the U.S. in late January 2026 for thalassemia. Requires a Risk Evaluation and Mitigation Strategy (REMS) due to hepatocellular injury risks.
- EU Approval: The EMA's CHMP adopted a positive opinion in October 2025 for PYRUKYND in thalassemia; final European Commission decision expected in early 2026.
- Sickle Cell Disease (SCD): Phase 3 RISE UP trial met the primary endpoint for hemoglobin response in November 2025. A pre-sNDA meeting with the FDA is scheduled for Q1 2026, with a marketing application intended to follow.
- Pipeline: Tebapivat Phase 2b enrollment completed (data expected H1 2026); AG-181 Phase 1 completed (Phase 1b expected H1 2026); AG-236 Phase 1 initiated (data expected H1 2026).
Risks and Contingencies
- Profitability: The company has an accumulated deficit of $561.7 million and expects to incur losses in the future. It may never achieve profitability.
- Liquidity: While the company holds $1.2 billion in cash, it relies on product sales and potential "Retained Earn-Out Rights" from the Vorasidenib sale (3% of U.S. net sales over $1.0 billion) for future funding. No committed external funding exists beyond these rights.
- Regulatory & Safety: AQVESME carries a boxed warning for hepatocellular injury. Failure to comply with REMS requirements could restrict sales. Clinical trial outcomes for SCD and other candidates remain uncertain.
- Third-Party Dependence: Reliance on third-party manufacturers and distributors (e.g., Avanzanite, NewBridge) introduces supply chain and commercialization risks.
Investor Verification Checklist
- Verify AQVESME Commercialization: Confirm the effectiveness of the REMS program and early sales uptake following the January 2026 launch.
- Monitor SCD Regulatory Path: Track the outcome of the Q1 2026 pre-sNDA meeting with the FDA regarding mitapivat for Sickle Cell Disease.
- Assess Cash Burn Rate: Evaluate if the $1.2 billion cash balance is sufficient to fund operations through the commercialization of AQVESME and the SCD application without dilutive financing.
- Review Tebapivat Data: Await H1 2026 topline data from the Phase 2b trial for LR MDS and SCD to validate the pipeline's depth.
- Check EU Decision: Confirm the final European Commission decision on the thalassemia indication expected in early 2026.